Physician profile
Seth D Potash
NPI 1043252273
$147,581.60
in general payments reported to CMS, 2019-2025
35 companies · $26K in 2025
The $26K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $23K · 2021: $25K · 2022: $10K · 2023: $9,671 · 2024: $33K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $38K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $11K · Travel and Lodging: $3,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,463.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,125.00 |
| Food and Beverage | $10,963.80 |
| Travel and Lodging | $3,459.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $41,629.19 | 2019-2025 | Idose, Istent Trabecular Micro-Bypass Stent System, Travoprost Intraocular Implant - Idose |
| Allergan, INC. | $34,173.37 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $29,353.77 | 2019-2021 | |
| Alcon Vision LLC | $20,614.35 | 2019-2025 | Rocklatan, Rhopressa, Simbrinza |
| Abbvie INC. | $9,911.43 | 2019-2025 | |
| New World Medical,INC. | $3,341.71 | 2020-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $1,832.91 | 2019-2024 | Tecnis Iol, Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $1,238.68 | 2019-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $1,106.82 | 2019-2022 | |
| Sight Sciences, INC. | $955.04 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $934.35 | 2022-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $461.58 | 2019-2023 | |
| Rxsight INC | $339.98 | 2024 | Rxsight Contact Lens, Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Harrow Eye, LLC | $178.90 | 2024-2025 | Vevye |
| Regeneron Healthcare Solutions, INC. | $137.84 | 2022-2024 | Eylea |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $137.65 | 2022-2024 | Tyrvaya |
| Horizon Therapeutics Plc | $131.58 | 2021-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $127.84 | 2024-2025 | Xdemvy |
| Eyepoint US, INC. | $118.43 | 2019-2022 | |
| Amgen INC. | $103.39 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $103.05 | 2019-2020 | |
| Alimera Sciences, INC. | $100.88 | 2020-2024 | Yutiq, Iluvien |
| Ivantis, INC | $80.63 | 2021 | |
| Astellas Pharma US INC | $77.18 | 2024-2025 | Izervay |
| Thea Pharma INC. | $73.20 | 2025 | Iyuzeh |
| Dompe US, INC. | $60.63 | 2021-2025 | Oxervate |
| Rayner Intraocular Lenses Limited | $60.18 | 2025 | Rayner Cataract Set 1, Rayone Aspheric, Rayone Emv |
| Shire North American Group INC | $46.05 | 2019 | |
| Biotissue Holdings INC. | $32.32 | 2022 | |
| Ocular Therapeutix, INC. | $28.64 | 2023-2024 | Dextenza |
| Eyevance Pharmaceuticals LLC | $24.61 | 2021 | |
| Boston Scientific Corporation | $21.43 | 2024 | |
| Merz Pharmaceuticals, LLC | $19.81 | 2023 | Xeomin |
| Omeros Corporation | $12.50 | 2019 | |
| Spark Therapeutics, INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Potash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.